The third meeting of Innovators in Urology took place in Dublin on 14±16 September 2000. Forty-two delegates from around the world gathered to discuss their latest research ®ndings in the form of poster presentations. The group were given advice on communication skills, as well as having access to media consultants. A selection of the research topics presented are summarised below. All abstracts will be published in full in Prostate Cancer and Prostatic Disease later this year.
Regulation of prostate cancer
Chris Evans (Sacramento, USA) reported on regulation of human prostate cancer. Vascular endothelial growth factor (VEGF) was shown to be produced by a series of human prostate cancer cell lines. Using an in vitro rat model, culture media containing VEGF increased microvessel permeability, a critical early angiogenic step. Other angiogenic factors measured included urokinase type plasminogen activator (u-PA) and its inhibitor, PAI-1, and basic ®broblast growth factor (bFGF). Another interesting ®nding was that prostate cancer tissue was able to convert plasminogen to angiostatin, an important step in regulating capillary tube formation.
Bill Watson (Dublin, Ireland) presented data from his research on the role of insulin-like growth factor-1 (IGF-1) in the resistance of prostate cancer cells to chemical-and radiation-induced apoptosis. Apoptosis was induced in PC-3 and LNCaP cells using radiation, etoposide or cycloheximide. However, pre-incubation of the cells with IGF-1 conferred resistance to apoptosis in both cell lines. Interestingly, bone, the principal site for metastases of prostate cancer, is rich in IGF-1 and these high levels may aid metastatic prostate cells to survive and proliferate. The implications of this research are that manipulation of IGF-1 signalling may be a therapeutic option in the treatment of androgen-independent prostate cancer, thought to be caused by the development of apoptotic resistance.
re®nement of local staging information as being useful in management decisions. This makes comparison between preoperative and pathological stage dif®cult, although the problem could be overcome with the introduction of national guidelines.
Gene therapy
Tumour angiogenesis has been studied as a target of gene therapy in human prostate cancer (Chris Wood, Texas, USA). Antisense adenoviral gene therapy targeting of bFGF, interleukin-8 (IL-8) and VEGF resulted in an 80± 90% reduction in tumour cell production of each of these angiogenic factors. Antisense adenoviral gene therapy of existing tumours in a nude mouse model resulted in a signi®cant reduction in tumour size, with a down regulation in markers of angiogenesis, including microvessel density. These early data suggest the potential of this system in the treatment of aggressive prostate cancers, possible in combination with other strategies.
Jonathan Eaton (London, UK) discussed an innovative approach to gene therapy, Genetic Prodrug Activation Therapy (GPAT), which can kill tumour cells by inserting suicide genes into cancer cells. The cancer cells then convert prodrugs into cytotoxic metabolites, resulting in cell death. As transfection rates are less than 100%, this system takes advantage of the 'bystander effect', which confers cytotoxicity onto neighbouring untransfected cells. A test system using adenovirus vectors resulted in transfection rates of 60±99% with the LnCaP cell line. Further work will focus on the adenovirus vector containing herpes simplex virus thymidine kinase/ ganciclovir.
Radical prostatectomy
Prostate-speci®c antigen (PSA) doubling time prior to radical prostatectomy was signi®cantly associated with ®nal pathologic ®ndings according to research conducted by Shin Egawa (Kitasato, Japan). PSA doubling times were calculated in 63 patients with prostate cancer. Stage pT3 disease was shown to be signi®cantly more common in patients with PSA doubling times of less than 36 months compared with those with doubling times of more than 36 months (P 0.04). Biochemical failure was also more common in patients with rapid PSA doubling times.
Fascial pubourethral sling at the time of radical retropubic prostatectomy in patients with high risk of incontinence was reported to decrease the risk of post-operative incontinence (Louis Pisters, Houston, USA). Risk factors for incontinence included salvage prostatectomy after radiation; prostatectomy after prior treatment; transurethral resection of the prostate; age over 65 y; and obesity. Of 28 patients evaluated at 3 months after surgery, 11 (39%) were continent (no pads); 11% (11/ 23) continence was reported at 6±9 months and 67% (6/9) at 1 year.
An analysis was conducted of a prospective database of patients undergoing pelvic lymphadenectomy and radical prostatectomy to help determine factors predictive of recovery of potency (Farhang Rabbani, New York, USA). Results showed that age, preoperative potency and preservation of the neurovascular bundles, but not clinical or pathologic stage, were independently predictive of potency after surgery.
Alternative therapies for prostate cancer
Simon Brewster (Oxford, UK) discussed a survey of alternative therapies for prostate cancer conducted on 100 patients in the Oxford area in the UK. Results indicate that of 60 respondents, over half were aware of alternative therapies for the prevention or treatment of the disease. The most common source of patients' awareness was newspapers and magazines. One-quarter of the survey group were actually taking alternative therapies relating to their prostate, the most common of which was selenium. Patients also expressed the opinion that doctors should discuss non-prescription medicines with their patients, even if there was no proven bene®t.
New UK government initiatives on prostate cancer
A new prostate cancer programme was launched by the UK Department of Health in early September. This will involve a fourfold increase in spending on prostate cancer in England; by the year 2003±4, the research funding will have reached 4.2 m ($6.3 m) per year. At the launch, the Health Secretary, Alan Milburn, was quoted as saying: This starts the implementation of improvements in cancer services. For too long not enough has been done to detect prostate cancer or to improve treatment.' Three percent of all male deaths (around 8500) in England and Wales are due to prostate cancer. Key measures in the new plan include:
1 By December 2000, men with suspected prostate cancer to be able to see a specialist within 14 days (after urgent referral from GP). 2 Introduction of a population-based screening programme for prostate cancer if and when new research leads to effective screening. 3 GPs to be given advice in revised guidelines on what to do when asymptomatic patients request a PSA test. 4 Any man considering a PSA test will be given detailed information to enable him to make an informed choice about whether to proceed with the test or not. 5 A prostate cancer risk management programme to be developed which will provide information to any man requesting a PSA test. 6 An extra 95 trained urologists to be employed by the National Health Service by 2005. This represents an increase of 3.4% in the number in training each year.
Emphasis was placed on the need to improve screening techniques so that a distinction can be made between those cancers that are slow growing and pose no risk to the patient and those which are growing rapidly and should be treated. Information is to be provided for patients through lea¯ets and a website explaining the implications of having a PSA test.
Tackling men's health
In addition to the speci®c programme on prostate cancer discussed above, the UK government have announced proposals to promote men's health and address gender inequalities in life expectancy. It is known that men die on average 5 y earlier than women and that this health gap is wider for men from less af¯uent backgrounds. With regard to speci®c problems in boys and young men, foetal mortality is higher in males than females; postnatal depression in mothers has a greater effect on boys than girls; boys are more likely to experience accidents; and suicide rates are four times higher in teenage boys than in girls. The Health Development Agency is a new agency speci®cally formed to deal with the promotion of men's health. Other initiatives include the setting up of smoking cessation clinics in low income areas and strategies to reduce men's alcohol consumption.
Novel cancer detection technique
A novel cancer detection technique has being developed at the National Aeronautics and Space Administration's (NASA's) Jet Propulsion Laboratory in Pasadena, CA, USA. The device involved is an advanced sensor called the BioScan System and works by detecting the cancer's ability to recruit a new blood supply, ie the process of angiogenesis. The Dana-Faber Cancer Institute, Boston, MA, USA is currently testing the device. Their goal is to evaluate the BioScan System's ability to monitor biological effects of cancer treatment and to help physicians detect treatment-induced changes in cancerous lesions of the breast, skin and other organs. Several new classes of anti-cancer drugs, including antiangiogenic factors will be tested. It is hoped that the technique will detect subtle yet important effects of new drugs, which might otherwise have been missed. In doing so, the BioScan System could assist in optimising biologically active doses and even reducing the time it takes to demonstrate a drug's ef®cacy. This technology might also allow the physician to monitor and individualise cancer treatment on a patient-by-patient basis.
New prostate tissue vaporisation technique
A new device that can vaporise prostatic tissue has been developed by Mark Goble, a UK-based urologist who has worked on the system over the past 10 years. The device works by creating a powerful plasma Ð a high temperature cloud of ionised atoms. Using an electrode that emits this cloud as an orange glow at its tip, the surgeon can vaporise prostate tissue quickly without any bleeding as the blood vessels are sealed during the process. The operation is conducted by key-hole techniques and takes no longer than present methods.
The device is made by Gyrus Medical, Bourne End, Bucks, UK and has been used in almost 200 patients over the past 12 months. According to Simon St Clair Carter, a consultant urologist at Hammersmith Hospital, London, UK, the clinical results are working out`extremely nicely'. This technique has the potential to change dramatically urological practice, with prostate surgery being turned into an outpatient procedure.
Prostate cancer antibody therapy
UroGenesys Inc. CA, USA have signed an agreement providing Genentech Inc., CA, USA with an exclusive worldwide license to develop antibody-based therapeutics for cancer using Prostate Stem Cell Antigen (PSCA) as a target antigen. UroGenesys already holds an exclusive license to PSCA-related patents from UCLA, USA and has been validating its potential as an antibody target in xenograft models of human cancer in mice.
PSCA is a cell surface protein whose expression is elevated in greater than 80% of all stages of prostate cancer, including bone metastatic lesions, and in the majority of bladder cancer patients.
Currently, over one million men in the USA have prostate cancer, with over 180 000 new cases diagnosed each year and 40 000 deaths attributed to the disease annually. The cost to the healthcare system is over $4.0 billion each year.
MAB in advanced prostate cancer: an overview
The Prostate Cancer Trialists' Collaborative Group have recently published an overview of the randomised trials on maximum androgen blockade (MAB) in advanced prostate cancer (Lancet 2000; 355: 1491±1498) . The main systemic treatment of advanced prostate cancer is androgen suppression, either by surgical castration (orchiectomy) or long-term use of a luteinising-hormone-releasing hormone (LHRH) agonist. Low plasma levels of androgens remaining after androgen suppression can be further reduced by the addition of an antiandrogen such as nilutamide,¯utamide, or cyproterone acetate (CPA). The combination of androgen suppression with an antiandrogen is referred to as MAB.
The Lancet report is of a collaborative meta-analysis of the mortality ®ndings from all the available trials of MAB vs androgen suppression in advanced prostate cancer; 27 trials were included involving 8275 men with metastatic (88%) or locally advanced (12%) prostate cancer. Half of the men were over 70 y of age and typical follow-up was 5 y.
A total of 5932 (72%) deaths occurred, 80% of which were attributable to prostate cancer. Five year survival was 25.4% with MAB vs 23.6% with androgen suppression alone (not signi®cant). No signi®cant heterogeneity in the treatment effect (MAB vs androgen suppression alone) was noted with respect to age or disease stage. Inclusion of CPA in the MAB regimen (20% of cases) appeared slightly unfavourable; 5-y survival: 15.4% MAB vs 18.1% androgen suppression alone. In contrast, results for nilutamide and¯utamide appeared slightly favourable; 5-y survival: 27.6% MAB vs 24.7% androgen suppression alone. Non-prostate cancer deaths, although not signi®cantly affected by treatment, accounted for some of the apparently adverse effects of CPA.
It was concluded that the addition of an antiandrogen to androgen suppression improved 5-y survival by about 2% or 3%, dependent on whether the analysis includes trials on CPA or not. Not all patients will need all of the tests and the treatment option chosen does have a role. Uro¯owmetry should be performed by all urologists seeing patients and PFS should be performed in all patients with complications and prior to invasive treatment.
International Consultation on BPH

Frequency-volume chart
This was considered in many ways to be better than a patient history or a symptom questionnaire. The test is particularly important in older men, where nocturnal polyuria (leading to cardiac failure) can be distinguished. A 2±7 day test duration was recommended, but it was acknowledged that 2 days was the normal time period.
Uro¯owmetry
This is a screening test in all patients and assessment of more than one void is preferred with a void volume b 150 ml, although this is patient dependent. Uro¯ow-metry cannot distinguish between BOO and detrusor underactivity. The speci®city of the maximum¯ow rate (Qmax) was stated as:
`10 ml/s: 90% of patients will be obstructed. 10±15 ml/s: 65% of patients will be obstructed b 15 ml/s: 30% of patients will be obstructed.
PVR
To identify a typical PVR, assessment should be made after two voids. Increased PVR does not distinguish between BOO and detrusor underactivity.
Filling cystometry
This is an extremely useful test as it provides evidence of detrusor overactivity, which is particularly important in older patients. It is also useful to be able to warn patients undergoing prostatectomy that the symptoms of detrusor overactivity are likely to eventually return. It is important to compare the results with the voided volumes on a frequency volume chart while doing ®lling cystometery so that the patient is not over®lled. Quality control is vital.
PFS
PFS con®rm the presence of BOO and assess detrusor contractility and again, quality control is vital. The use of the International Continence (ICS) nomogram is recommended as this allows the distinction between patients who are obstructed (high pressure, low¯ow), slightly obstructed or not obstructed (high¯ow, low pressure). Several artefacts in pressure¯ow traces have been identi®ed, eg poor pressure transmission, incorrect zero position, loss of signal and no scaling on charts, and it is important that they are interpreted correctly. A number of strong recommendations were made, including:
Correct zero setting. Calibration of the transducer. Recommended pressure reference level to be followed. Plausibility test prior to testing, eg intravesical and intra-abdominal pressures should both be positive (5± 50 mmH 2 O). No decline in pressure during ®lling.
There are a number of myths regarding PFS, including:
Cost: money would be saved if surgery was conducted only on obstructed patients. Morbidity: infection is only 1±2%. Unreliability: this will be the case with poor technique. PFS are not needed to diagnose BOO. Not clear how to identify BOO based on PFS: ICS nomogram is the proper tool to use.
In general, if obstruction is present then a better symptomatic response rate is possible; older patients with detrusor overactivity or underactivity do less well than younger men with proven obstruction without detrusor overactivity. Standardised outcome measures are needed for assessing patients after out¯ow tract surgery and these should be developed in the future.
Conclusion
The committee supported: Accurate nomenclature. Systematic functional assessment of voiding tailored to the treatment option. If surgery is to be carried out on a patient with BOO, then the advantages/disadvantages of a precise measurement of BOO prior to surgery to be discussed with the patient. Audit and quality control of personnel carrying out urodynamic testing.
